We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / Company / Media & Events / Press releases & publications

Press releases & publications

Novasep: Most Promising Pharma and Life Sciences Solution Provider

Novasep: Most Promising Pharma and Life Sciences Solution Provider

25 Nov 2021

Novasep has been designated by CIO Review as one of the most promising Pharma and Life Sciences solution providers in 2021!
Discover our approach explained by Jin Seok HUR, General Manager of Novasep’s Boothwyn (PA) US site, in this article.


Notification of exercise of a drag-along obligation by NVHL S.A.

McSAF and Novasep announce their successful collaboration to produce a next-generation Antibody-Drug Conjugate (ADC)

The Auvergne-Rhône-Alpes Region provides Novasep a grant to finance its “Data Lake for the Industry 4.0” project

Novasep launches Hipersep® Process M, its new commercial-scale HPLC chromatography system, for the development and production of pharmaceuticals

Novasep launches Hipersep® Process M, its new commercial-scale HPLC chromatography system, for the development and production of pharmaceuticals

20 Oct 2021

Novasep continues to lead and innovate in the development and production of pharmaceutical molecules and announces the launch of a new industrial-scale HPLC system that is faster, safer, and more productive than ever: Hipersep® Process M

• A new unit designed for high-pressure chromatography up to 100 bars, suitable for purification processes requiring high temperatures (up to 85°C)
• A wide range of flow rates (20 to 500 l/h) for more flexibility
• A sanitary design for faster, easier, and more efficient cleaning


PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale.

Fire quickly controlled at the Mourenx site/ Départ de feu maîtrisé sur notre site de Mourenx

Fire quickly controlled at the Mourenx site/ Départ de feu maîtrisé sur notre site de Mourenx

06 Sep 2021

• Fire quickly extinguished/ Un départ de feu maîtrisé rapidement
• No injuries or damage/ Pas de blessé, ni de dommage matériel
• No environmental impact/ Aucun impact sur l’environnement


Novasep signs a manufacturing services agreement with Exelixis for a next-generation ADC

Novasep signs a manufacturing services agreement with Exelixis for a next-generation ADC

06 Jul 2021

• The agreement covers the cGMP clinical manufacturing of a next-generation ADC drug candidate
• Novasep’s Le Mans site, in France, has already manufactured the ADC for Exelixis’ ongoing phase 1 clinical trial
• Novasep leverages its ADC bioconjugation expertise and process development capabilities in support of promising new cancer treatments


Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site

Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site

24 Jun 2021




• Novasep continues its investment strategy by upgrading its API manufacturing facility at its Mourenx site, increasing its flexibility and competitiveness
• A €6.1 million investment will be made over 3 years
• This investment has been selected by the French Government to be supported by ‘France Relance’, the post-Covid recovery plan
• 7 full-time jobs to be created


Top Pharma Outsourcing companies in Europe

Top Pharma Outsourcing companies in Europe

07 Jun 2021

Novasep has been recognized as one of the Top Pharma Outsourcing companies in Europe in 2021!
Discover our CDMO services presented by Jean Blehaut, President of Novasep’s Pharma Solutions Business Unit.



You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Your brochure is ready!

X

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Give us your feedback!